Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL20580644

Clc1cc(N2CCNCC2)c2cn[nH]c2c1.O=C(O)C(F)(F)F

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 6/20 0.41
HTR2B P41595 6/20 0.41
HTR6 P50406 6/20 0.41
HTR1A P08908 5/20 0.41
HTR3A P46098 4/20 0.41
HTR2A P28223 3/20 0.41
HTR5A P47898 2/20 0.41
HTR2C P28335 2/20 0.40
CHRNB2 P17787 2/20 0.40
CHRNA4 P43681 2/20 0.40
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
ADRB2 P07550 2/20 0.39
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
ADRB1 P08588 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
BACE1 P56817 2/20 0.38
HTR1D P28221 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21894610 0.88 HTR7 (0.50) HTR7HTR2BHTR6HTR1AHTR3A
SCHEMBL17739101 0.83 HTR1A (0.54) HTR7HTR2BHTR6HTR1AHTR3A
SCHEMBL17738883 0.78 MEN1 (0.41)
SCHEMBL17739564 0.77 NOTUM (0.47) METAP2
SCHEMBL20916930 0.77 POLB (0.47) HTR7HTR2BHTR6HTR1AHTR3A
SCHEMBL21894564 0.76 CLK1 (0.47)
SCHEMBL17738872 0.76 TRPV1 (0.44) HTR7HTR6HTR1AHTR2AHSP90AA1
SCHEMBL17738718 0.76 ALDH1A1 (0.49) HTR7HTR2BHTR6HTR1AHTR3A
SCHEMBL17738580 0.75 CYP11B1 (0.43)
SCHEMBL23534492 0.75 METAP2 (0.41) METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11130738-B2 Pharmaceutical compound IOMET PHARMA LTD. (GB) 2021-09-28 US disclosed
US-20200172492-A1 PHARMACEUTICAL COMPOUND IOMET PHARMA LTD. (GB) 2020-06-04 US disclosed
US-10590086-B2 Pharmaceutical compound IOMET PHARMA LTD. (GB) 2020-03-17 US disclosed
US-20180354908-A1 PHARMACEUTICAL COMPOUND IOMET PHARMA LTD. (GB) 2018-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11130738-B2 Pharmaceutical compound IDO1, TDO2, IDO2 HTR7 61/4885HTR2B 175/4885HTR6 21/4885
US-20200172492-A1 PHARMACEUTICAL COMPOUND IDO1, TDO2, IDO2 HTR7 61/4885HTR2B 175/4885HTR6 21/4885
US-10590086-B2 Pharmaceutical compound IDO1, TDO2, IDO2 HTR7 61/4885HTR2B 175/4885HTR6 21/4885
US-20180354908-A1 PHARMACEUTICAL COMPOUND IDO1, TDO2, IDO2 HTR7 61/4885HTR2B 175/4885HTR6 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.